GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE Drug Patent Profile

When do Guaifenesin And Pseudoephedrine Hydrochloride patents expire, and when can generic versions of Guaifenesin And Pseudoephedrine Hydrochloride launch?

Guaifenesin And Pseudoephedrine Hydrochloride is a drug marketed by Actavis Labs Fl, Aurobindo Pharma Ltd, Dr Reddys, Granules, L Perrigo Co, and Sun Pharm Inds Inc. and is included in six NDAs.

The generic ingredient in GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE is guaifenesin; pseudoephedrine hydrochloride. There are twenty drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the guaifenesin; pseudoephedrine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Guaifenesin And Pseudoephedrine Hydrochloride

A generic version of GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE was approved as guaifenesin; pseudoephedrine hydrochloride by ACTAVIS LABS FL on May 27^th, 2015.

Summary for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

US Patents:	0
Applicants:	6
NDAs:	6

US Patents and Regulatory Information for GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Actavis Labs Fl	GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE	guaifenesin; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	091071-001	May 27, 2015		OTC	No	No
Granules	GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE	guaifenesin; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	216082-002	Aug 22, 2022		DISCN	No	No
Aurobindo Pharma Ltd	GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE	guaifenesin; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	213203-001	Mar 25, 2020		OTC	No	No
Sun Pharm Inds Inc	GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE	guaifenesin; pseudoephedrine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	212542-001	Apr 28, 2020		OTC	No	No

Guaifenesin and Pseudoephedrine Hydrochloride: Market and Patent Landscape Analysis

Last updated: February 19, 2026

Guaifenesin and pseudoephedrine hydrochloride, a fixed-dose combination drug, offers symptomatic relief for cough, congestion, and chest congestion. The market is influenced by generic competition and evolving regulatory landscapes, particularly concerning pseudoephedrine's availability. Key patents protecting specific formulations or manufacturing processes are expiring, creating opportunities for generic manufacturers.

What is the current market size and projected growth for guaifenesin and pseudoephedrine hydrochloride?

The market for guaifenesin and pseudoephedrine hydrochloride is substantial, driven by its widespread use in over-the-counter (OTC) and prescription cough and cold remedies. While precise, up-to-the-minute market size figures for this specific combination are often aggregated within broader respiratory or cough and cold segments, industry reports indicate a consistent demand.

The global cough and cold remedies market was valued at approximately USD 50 billion in 2023 [1]. Within this segment, expectorant and decongestant combinations like guaifenesin and pseudoephedrine hydrochloride constitute a significant portion. Projections for the broader cough and cold market anticipate a compound annual growth rate (CAGR) of 3% to 5% over the next five to seven years, reaching an estimated USD 70 billion by 2030 [2]. This growth is attributed to factors including aging populations, increasing prevalence of respiratory infections, and a growing demand for effective symptomatic relief.

However, the market dynamics for this specific combination are also influenced by the accessibility of pseudoephedrine. Regulatory restrictions implemented in various regions to curb the illicit manufacture of methamphetamine have led to a shift towards alternative decongestants in some OTC formulations. This has created a bifurcated market where prescription-only access or regional limitations for pseudoephedrine-containing products exist, potentially impacting the overall market penetration of this specific combination compared to formulations utilizing phenylephrine or other alternatives.

What are the key therapeutic indications and patient populations for guaifenesin and pseudoephedrine hydrochloride?

Guaifenesin and pseudoephedrine hydrochloride is indicated for the temporary relief of symptoms associated with the common cold, flu, bronchitis, and other respiratory conditions. The primary therapeutic benefits are:

• Expectorant Action (Guaifenesin): Helps to loosen and thin mucus in the airways, making it easier to cough up. This addresses symptoms of chest congestion and productive coughs.
• Nasal Decongestant Action (Pseudoephedrine Hydrochloride): Reduces swelling of blood vessels in the nasal passages, thereby decreasing nasal congestion and sinus pressure. This alleviates symptoms of a stuffy nose.

The combination is therefore prescribed or recommended for patients experiencing a combination of:

• Cough with mucus
• Chest congestion
• Nasal congestion
• Sinus pressure

Patient Populations:

The drug is used across a broad patient demographic, excluding very young children due to dosage and safety considerations for pseudoephedrine.

• Adults: This is the primary patient group.
• Adolescents: Typically aged 12 and above, depending on product labeling and physician discretion.
• Patients with specific respiratory conditions: Including those with acute bronchitis, sinusitis, and exacerbations of chronic conditions where mucus buildup is a significant symptom.

It is important to note that contraindications and precautions apply, particularly for individuals with certain pre-existing medical conditions such as hypertension, heart disease, thyroid disease, diabetes, and glaucoma, due to the stimulant effects of pseudoephedrine.

What is the patent landscape for guaifenesin and pseudoephedrine hydrochloride formulations and manufacturing processes?

The patent landscape for guaifenesin and pseudoephedrine hydrochloride is characterized by a history of composition of matter patents for the individual active pharmaceutical ingredients (APIs) that have long since expired. Current patent activity primarily focuses on:

• Formulation Patents: These patents cover novel drug delivery systems, extended-release mechanisms, or specific ratios of the active ingredients designed to improve efficacy, reduce side effects, or enhance patient compliance.
• Manufacturing Process Patents: These patents protect innovative methods for synthesizing or purifying guaifenesin or pseudoephedrine hydrochloride, or for manufacturing the fixed-dose combination product. This can include patents on specific crystallization techniques, impurity profiling, or granulation methods.
• Polymorph Patents: Discoveries of new crystalline forms (polymorphs) of the active ingredients that offer improved stability, solubility, or bioavailability can be patented.

Key Patent Expirations and Opportunities:

Many foundational patents for guaifenesin and pseudoephedrine hydrochloride have expired, allowing for the widespread availability of generic versions of standard formulations. However, patent expiry dates for newer, improved formulations or advanced manufacturing processes are critical for market entry analysis.

As of the present, a significant number of patents related to basic formulations of guaifenesin and pseudoephedrine hydrochloride have expired. For instance, patents covering immediate-release tablets or syrups with standard API ratios have largely lapsed in major markets like the United States and Europe.

Recent and Upcoming Patent Expirations of Note:

While specific patent numbers are dynamic and require in-depth database searches, the general trend indicates that patents covering:

• Extended-Release Formulations: These were often developed to provide longer-lasting symptom relief and reduce dosing frequency. Expiration dates for these patents can extend further, providing exclusivity for their developers for a longer period. For example, a patent covering a specific extended-release matrix technology for a guaifenesin/pseudoephedrine product might have had an expiry in the mid-2010s or late 2020s.
• Novel Combinatorial Ratios or Synergistic Formulations: Patents protecting specific combinations or ratios that aim for enhanced therapeutic effect or reduced side effects can also have staggered expiry dates.
• Manufacturing Process Improvements: Patents on streamlined or cost-effective manufacturing processes, particularly those leading to higher purity or yields, can also represent opportunities for generic companies upon their expiry. These can be highly valuable as they directly impact the cost of goods sold.

Challenges and Considerations for Generic Entry:

• Regulatory Hurdles: The primary challenge for new generic entrants is often navigating the regulatory approval process, which can be lengthy and costly.
• Bioequivalence Studies: Demonstrating bioequivalence to the reference listed drug is a mandatory step for generic approval.
• Impurity Profiles: Minor differences in impurity profiles between generic and branded products can sometimes lead to regulatory scrutiny.
• Market Exclusivity: Even after patent expiry, the first generic to file can sometimes receive a period of market exclusivity.

Strategic Implications:

The absence of strong, remaining composition of matter patents on the core APIs means that competition is driven by formulation innovation, manufacturing efficiency, and market access strategies. Companies with patents on advanced delivery systems or more efficient manufacturing processes will continue to benefit from market exclusivity until those specific patents expire. For generic manufacturers, identifying formulation patents that have expired or are nearing expiration presents opportunities for developing and marketing equivalent products.

What are the regulatory considerations and restrictions surrounding pseudoephedrine?

The regulatory landscape for pseudoephedrine is complex and significantly impacts the availability and market dynamics of guaifenesin and pseudoephedrine hydrochloride. Pseudoephedrine is a precursor chemical used in the illicit manufacture of methamphetamine, leading to stringent regulations in many countries.

Key Regulatory Frameworks and Restrictions:

• Combat Methamphetamine Epidemic Act of 2005 (CMEA) in the United States: This federal law placed restrictions on the sale of OTC products containing pseudoephedrine.

  • Behind-the-Counter (BTC) Placement: Products containing pseudoephedrine must be kept behind the pharmacy counter, requiring identification for purchase and limiting the quantity that can be purchased within a specified period (e.g., 3.6 grams per day and 9 grams per 30-day period for non-prescription sales).
  • Record Keeping: Retailers are required to maintain logs of pseudoephedrine sales.
  • Exempt from Scheduling: While restricted, pseudoephedrine is not a scheduled controlled substance.

• State-Level Regulations: Many U.S. states have implemented additional or stricter regulations than federal law, including:

  • Prescription Requirements: Some states require a prescription for all pseudoephedrine-containing products, effectively removing them from OTC status. Examples include Oregon and Mississippi [3].
  • Electronic Logging Systems: Mandatory use of electronic tracking systems for pseudoephedrine sales to prevent circumventing purchase limits.

• International Regulations: Similar restrictions exist globally, though the specifics vary:

  • Canada: Pseudoephedrine is classified as a prescription-only medication.
  • Australia: Pseudoephedrine is available only from a pharmacist under strict controls.
  • European Union: Regulations vary by member state, with many implementing strict controls or preferring alternative decongestants.

Impact on Guaifenesin and Pseudoephedrine Hydrochloride:

• Market Fragmentation: The varying state and international regulations create a fragmented market. Products that are readily available OTC in one region may be prescription-only or unavailable in another.
• Shift to Alternatives: The restrictions have driven manufacturers to reformulate some OTC products using alternative decongestants, most notably phenylephrine. However, the efficacy of phenylephrine as an oral decongestant has been questioned by some regulatory bodies and scientific reviews [4].
• Reduced Consumer Access: Consumers may find it more difficult or inconvenient to purchase guaifenesin and pseudoephedrine hydrochloride, potentially leading them to seek alternative treatments.
• Increased Costs for Manufacturers: Compliance with logging, security, and dispensing requirements adds operational complexity and cost for manufacturers and pharmacies.

Future Outlook:

The trend towards stricter regulation of pseudoephedrine is likely to continue as governments prioritize efforts to combat methamphetamine production. This may lead to further limitations on its availability or a complete shift towards prescription-only status in more jurisdictions. Pharmaceutical companies must closely monitor these evolving regulations and adapt their product portfolios and distribution strategies accordingly.

What are the key competitors and market positioning strategies for guaifenesin and pseudoephedrine hydrochloride products?

The market for guaifenesin and pseudoephedrine hydrochloride is characterized by a blend of established branded products, generic alternatives, and a growing presence of products formulated with alternative decongestants.

Key Competitors:

1. Branded Products:

   • Mucinex D (Reckitt Benckiser): A leading brand in the expectorant category, often associated with guaifenesin. While Mucinex D contains guaifenesin and pseudoephedrine, Reckitt Benckiser has also heavily promoted its phenylephrine-based "Non-Drowsy" formulations (e.g., Mucinex Fast-Acting).
   • Robitussin DM Max (Pfizer): Another prominent brand offering guaifenesin and dextromethorphan hydrobromide, with some variants also containing pseudoephedrine or phenylephrine.
   • Claritin-D (Bayer/Schering-Plough): While primarily an antihistamine, some formulations combine loratadine with pseudoephedrine for comprehensive allergy and cold symptom relief, representing indirect competition for decongestant needs.

2. Generic Manufacturers:

   • A large number of generic pharmaceutical companies produce guaifenesin and pseudoephedrine hydrochloride products. These include companies like:
     • Perrigo
     • Teva Pharmaceuticals
     • Sandoz (Novartis)
     • Lupin Pharmaceuticals
     • Various smaller regional manufacturers.
   • Generic competition primarily focuses on price and availability, especially for standard immediate-release formulations.

3. Products with Alternative Decongestants:

   • A significant competitive force comes from products formulated with phenylephrine, such as Sudafed PE (Johnson & Johnson) and numerous generic equivalents. These are positioned as alternatives where pseudoephedrine is restricted or unavailable.
   • Other decongestants like oxymetazoline (nasal spray) and epinephrine (inhalers) compete for the broader decongestant market but not directly as oral combination products.

Market Positioning Strategies:

• Established Brand Recognition and Trust: Branded products like Mucinex D leverage extensive marketing campaigns and brand loyalty to maintain market share. They position themselves on perceived efficacy and doctor recommendations.
• Price Competitiveness (Generics): Generic manufacturers compete primarily on price. Their strategy revolves around cost-effective manufacturing and efficient distribution to capture market share from branded products once patents expire or for standard formulations.
• Formulation Innovation: Companies develop and patent novel formulations (e.g., extended-release, unique liquid suspensions, combination with other active ingredients) to differentiate their products and extend patent protection. This allows them to command premium pricing.
• Regulatory Navigation and Product Reformulation: Manufacturers adept at navigating the complex regulatory landscape for pseudoephedrine are well-positioned. This includes:
  • Maintaining behind-the-counter availability where permitted.
  • Developing and extensively marketing alternative products with phenylephrine or other decongestants in regions where pseudoephedrine is heavily restricted.
  • Focusing on prescription-only markets for pseudoephedrine products where they remain viable.
• Targeted Marketing: Some products are marketed towards specific symptoms (e.g., "chest congestion and stuffy nose") or patient needs (e.g., "non-drowsy").
• Distribution Channel Strategy: Ensuring wide availability through major retail pharmacies, supermarkets, and online platforms is crucial. For pseudoephedrine products, managing behind-the-counter logistics is a key operational element.

The strategic landscape is dynamic, with a constant interplay between patent expiry, regulatory pressures on pseudoephedrine, and the emergence of alternative formulations. Companies that can innovate in formulation, efficiently manage regulatory compliance, and effectively market their products across different market segments are best positioned for success.

What are the manufacturing considerations and supply chain challenges for guaifenesin and pseudoephedrine hydrochloride?

Manufacturing and supplying guaifenesin and pseudoephedrine hydrochloride involves several critical considerations, particularly due to the nature of pseudoephedrine and the need for pharmaceutical-grade production.

Manufacturing Considerations:

1. API Sourcing and Quality Control:

   • Guaifenesin: Typically synthesized through established chemical processes. Manufacturers must ensure a reliable supply of high-purity guaifenesin.
   • Pseudoephedrine Hydrochloride: Sourcing pseudoephedrine HCl is subject to significant regulatory oversight due to its precursor status. Manufacturers must work with approved suppliers who comply with all national and international precursor chemical regulations (e.g., DEA regulations in the U.S.).
   • Impurity Profiling: Strict quality control is essential to identify and quantify impurities in both APIs. Regulatory bodies require detailed impurity profiles, and any deviations can lead to batch rejection or regulatory action.

2. Formulation and Dosage Form Production:

   • Fixed-Dose Combination: Precisely combining guaifenesin and pseudoephedrine hydrochloride in specific ratios is critical for efficacy and safety.
   • Dosage Forms: Common dosage forms include tablets, capsules, and liquid syrups. Each form requires specialized manufacturing equipment and processes:
     • Tablets/Capsules: Involve blending, granulation (wet or dry), compression, and potentially coating. Uniform distribution of both APIs is paramount.
     • Liquid Syrups: Require careful formulation to ensure API stability, palatability, and accurate dosing, often involving suspending agents, sweeteners, and flavorings.
   • Extended-Release Technologies: If producing extended-release versions, advanced manufacturing techniques such as matrix systems, osmotic pumps, or coated pellets are employed, requiring specialized expertise and equipment.

3. Good Manufacturing Practices (GMP):

   • All manufacturing must adhere to stringent GMP guidelines established by regulatory authorities (e.g., FDA, EMA). This covers facility design, equipment validation, personnel training, process control, documentation, and quality assurance.
   • Traceability of raw materials through to finished products is a core GMP requirement.

Supply Chain Challenges:

1. Pseudoephedrine Precursor Controls:

   • Strict Regulations: The most significant challenge is the stringent regulatory framework governing pseudoephedrine. This includes tracking, reporting, and security requirements at every stage of the supply chain, from API import to product distribution.
   • Supplier Vetting: Manufacturers must rigorously vet their pseudoephedrine suppliers to ensure compliance and avoid disruptions.
   • Inventory Management: Balancing the need for sufficient inventory with the risk of holding controlled substances under strict security protocols can be complex.

2. Logistical Complexity:

   • Behind-the-Counter (BTC) Distribution: For OTC products in regulated markets like the U.S., managing the logistics of dispensing pseudoephedrine-containing products from behind the pharmacy counter requires specific protocols and training for pharmacy staff.
   • Regional Variations: Navigating different precursor control laws and OTC/prescription status across various states and international markets adds significant logistical complexity.

3. API Availability and Price Volatility:

   • While guaifenesin is generally widely available, the supply and pricing of pseudoephedrine can be more volatile due to regulatory shifts and global demand.
   • Geopolitical factors or changes in manufacturing capacity by key global suppliers can impact availability.

4. Counterfeit and Diversion Risks:

   • The high value and controlled nature of pseudoephedrine make the supply chain susceptible to counterfeiting and diversion for illicit purposes. Robust security measures and supply chain integrity are essential.

5. Product Reformulation and Transition:

   • As regulations tighten on pseudoephedrine, manufacturers may need to transition to alternative decongestants (e.g., phenylephrine). This involves significant R&D, reformulation, re-validation, and regulatory re-approval processes, impacting production lines and supply chain configurations.

Companies that can effectively manage these manufacturing complexities and supply chain challenges, particularly those related to pseudoephedrine, will maintain a competitive advantage. Investment in secure sourcing, robust quality systems, and adaptable supply chain logistics is crucial.

Key Takeaways

• The market for guaifenesin and pseudoephedrine hydrochloride is a segment within the larger cough and cold remedies market, driven by consistent demand for symptomatic relief of respiratory conditions.
• Patent protection for guaifenesin and pseudoephedrine hydrochloride primarily resides in advanced formulations and manufacturing processes, as foundational composition of matter patents have expired.
• Pseudoephedrine is subject to significant regulatory restrictions globally due to its use as a methamphetamine precursor, impacting product availability and leading to market segmentation and a shift towards alternative decongestants in some regions.
• Key competitors include established branded products, numerous generic manufacturers, and a growing number of products utilizing alternative decongestants like phenylephrine.
• Manufacturing and supply chain operations are critically impacted by the stringent regulations governing pseudoephedrine, requiring robust quality control, secure sourcing, and adherence to GMP standards.

Frequently Asked Questions

1. Are there any remaining composition of matter patents for guaifenesin and pseudoephedrine hydrochloride? No, the primary patents covering the composition of matter for guaifenesin and pseudoephedrine hydrochloride have long since expired, allowing for the development of generic products.

2. What is the primary regulatory concern with pseudoephedrine? The primary regulatory concern is its use as a precursor in the illicit manufacture of methamphetamine, leading to strict controls on its sale and distribution in many countries.

3. What are the main strategies companies use to compete in this market? Competition strategies include brand recognition, price competitiveness for generics, formulation innovation (e.g., extended-release), and effective navigation of regulatory restrictions for pseudoephedrine.

4. How do regulatory restrictions on pseudoephedrine affect market access for guaifenesin and pseudoephedrine hydrochloride? Restrictions often lead to products being placed behind pharmacy counters, requiring prescriptions in some regions, or being replaced by formulations using alternative decongestants, fragmenting market access.

5. What are the critical manufacturing considerations for pseudoephedrine-containing products? Critical considerations include sourcing APIs from approved suppliers under strict precursor controls, maintaining rigorous impurity profiling, adhering to GMP, and managing the logistics of behind-the-counter dispensing where applicable.

Citations

[1] Grand View Research. (2023). Cough & Cold Remedies Market Size, Share & Trends Analysis Report By Product Type (Expectorants, Antitussives, Decongestants, Antihistamines), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online), By Region, And Segment Forecasts, 2023 - 2030. [2] Mordor Intelligence. (2023). Cough and Cold Remedies Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028). [3] National Conference of State Legislatures. (2021). Methamphetamine Precursors. Retrieved from https://www.ncsl.org/research/public-health/methamphetamine-precursors.aspx [4] U.S. Food and Drug Administration. (2023). FDA Update on Phenylephrine. Retrieved from https://www.fda.gov/drugs/postmarket-drug-safety-information-for-patients-and-providers/fda-update-phenylephrine